Methocarbamol is also sometimes used off-label orally to manage and treat sore backs and muscle strain. Methocarbamol is also prescribed as a prophylactic for horses that experience exertional rhabdomyolysis or “tying up,” which can cause muscle breakdown. Methocarbamol is a depressant and may affect performance and coordination. 

Bryant Ranch Prepack is voluntarily recalling one lot of methocarbamol 500 mg tablets to the consumer level. The bottles labeled as methocarbamol 500mg tablets have been found to contain methocarbamol 750 mg Tablets.

Risk Statement: If a patient takes a 750 mg tablet of methocarbamol instead of the prescribed 500 mg tablets, it potentially could result in excessive central nervous system depression, which may result in nausea, sedation, fainting, falls, seizure, coma, and death. Bryant Ranch Prepack has not received any reports of adverse events related to this recall.

The product is used together with rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions and is packaged in a white round bottle with a red and white label, which reads methocarbamol 500 mg packaged in counts of 30 (NDC:7133517952), 60 (NDC: 7133517954), and 90 (NDC:7133517957) pills. The affected methocarbamol 500 mg lots include the following Lot Number 163935/ Exp. Date 10/22. The product can be identified by red and white label with a yellow border at the top and bottom of the label, top of the label reads “Packaged by Bryant Ranch Prepack”, labels are pictured below. The methocarbamol 500 mg was distributed nationwide to multiple physician offices.

Bryant Ranch Prepack is notifying its distributors and customers by letter and email and is arranging for return of all recalled products. Consumers that have the bottles labeled as methocarbamol 500 mg tablets which are being recalled should stop using immediately and return to place of purchase and/or contact their physician. Distributors/physicians should stop distribution and contact Bryant Ranch Prepack to return the product immediately.

Consumers with questions regarding this recall can contact Bryant Ranch Prepack by phone at 877-885-0882 Mon.-Fri. 7am-6pm PST or compliance@brppharma.com. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

• Complete and submit the report online
• Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

The post Pharmaceutical Company Issues Voluntary Recall Of Methocarbamol Tablets Labeled In Wrong Concentration appeared first on Horse Racing News | Paulick Report.

Source of original post

Many stores that sell dewormer have added verbiage to the products that indicate that they are not safe for human consumption and are an unproven cure for COVID-19; other stores have removed ivermectin products from their shelves completely.

Ivermectin first came on the radar as a possible “cure” for COVID in 2020, when Monash University researchers reported that the drug could kill coronavirus in 48 hours in a lab setting. Though researchers at the Australian institution stressed that further testing was needed to establish the effectiveness and dosage of the drug, the public began seeking out ivermectin.

To date, completed studies on the efficacy of ivermectin are small and not considered of sufficient quality by researchers, though there are several studies currently underway. Reliable evidence doesn't support ivermectin use as a treatment or prophylactically for COVID-19.

Human-grade ivermectin is approved by the FDA for treatment of some parasitic worms and of some external parasites. Animal-grade ivermectin is not approved or dosed for humans and should never be ingested by humans. Side effects of taking livestock-grade ivermectin include nausea, diarrhea, vomiting, skin rash, facial or limb swelling, decreased blood pressure, liver problems and neurologic issues like dizziness and seizures.

Read more at Slate.com.

Read the full study here.

The post Potentially Life-Threatening COVID “Cure” Sees Dewormer Sales Surging appeared first on Horse Racing News | Paulick Report.

Source of original post

Though the number of equine fatalities from horse racing is decreasing, California, Kentucky, and New York have seen increased racing fatalities in 2018. Lead researcher Dr. Jessica Leatherwood says that a primary concern regarding these breakdowns is the off-label use of bisphosphonates; the study will assist in determining the effects of the drug on developing skeletons.

There is currently no scientific data exploring the effects of bisphosphonate use on young, exercising horses. The study, “Bisphosphonate Pharmacokinetics and Comprehensive Effects on Juvenile Cartilage, Bone Growth and Healing: Implications for Animal Welfare,” received a $500,000 grant from the U.S. Department of Agriculture's National Institute of Food and Agriculture. The particular bisphosphonate that will be studied is clodronate disodium, which is easy to administer and popular.

Racing commissions acknowledge the off-label use of bisphosphonates, but laboratories are unable to reliably test for the drug, limiting the ability to regulate off-label use.

Radiographs are often a key to racehorse sales, particularly in young horses where they expose skeletal health. Off-label use of bisphosphonates may mask potential flaws and cause microdamage accumulation, which could lead to breakdowns. The concern over bisphosphonate use isn't limited to racing; some sport horse disciplines are also limiting or restricting their use.

Horse and sheep models will be used in the study. As sheep are typically processed before they are two years old, they will offer insight into the potential changes in bone and biomechanical properties. The team hypothesizes that younger animals will clear the bisphosphonates more rapidly than older animals, that the drug alters bone in young, exercising horses, and that it will also have anti-inflammatory effects on the joint.

The findings could help shape new regulatory policies on bisphosphonate use in young horses.

Read more at Texas A&M AgriLife.

The post Bisphosphonate Use In Young Horses The Focus Of Texas A&M Study appeared first on Horse Racing News | Paulick Report.

Source of original post